A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade

Hermanns, T.; Savio, A. J.; Olkhov-Mitsel, E.; Mari, A.; Saba, K.; Bhindi, B.; Gill, B.; Sykes, J.; Kuk, C.; Poyet, C.; Wild, P. J.; Noon, A.; Bashir, S.; Juvet, T.; Rendon, R. A.; Waltregny, D.; Van Der Kwast, T.; Finelli, A.; Kulkarni, G. S.; Fleshner, N. E.; Lo, K.; Bapat, B.; Zlotta, A. R.

doi:10.1016/S1569-9056(19)30228-3

Aberrant DNA methylation is very common in bladder cancer (BC) pathogenesis and progression. These epigenetic alterations are detectable in voided urine and might be useful as non-invasive urinary biomarkers for the early detection of BC. Our multi-centric study supports the promise of epigenetic urinary markers in non-invasively detecting bladder cancer and discriminating between grades. Validation in different clinical settings including patients with hematuria, bladder cancer surveillance or screening in high-risk populations is warranted to support its utility.

A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade / Hermanns, T.; Savio, A.J.; Olkhov-Mitsel, E.; Mari, A.; Saba, K.; Bhindi, B.; Gill, B.; Sykes, J.; Kuk, C.; Poyet, C.; Wild, P.J.; Noon, A.; Bashir, S.; Juvet, T.; Rendon, R.A.; Waltregny, D.; Van Der Kwast, T.; Finelli, A.; Kulkarni, G.S.; Fleshner, N.E.; Lo, K.; Bapat, B.; Zlotta, A.R.. - In: EUROPEAN UROLOGY. SUPPLEMENTS. - ISSN 1569-9056. - ELETTRONICO. - 18:(2019), pp. e314-e314. [10.1016/S1569-9056(19)30228-3]